TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Sees Significant Decrease in Short Interest

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) was the recipient of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 49,400 shares, a decrease of 61.5% from the February 13th total of 128,400 shares. Based on an average daily volume of 260,900 shares, the short-interest ratio is currently 0.2 days. Approximately 176.4% of the company’s stock are sold short.

TC Biopharm Trading Up 2.4 %

TC Biopharm stock traded up $0.04 on Friday, hitting $1.73. The company’s stock had a trading volume of 44,581 shares, compared to its average volume of 93,059. TC Biopharm has a one year low of $1.43 and a one year high of $523.20. The company has a fifty day moving average price of $4.66 and a 200-day moving average price of $32.57.

Analysts Set New Price Targets

Separately, HC Wainwright decreased their target price on TC Biopharm from $112.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, December 6th.

TC Biopharm Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.